An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
By Stephen J. Ubl | November 18, 2020
This year our industry has worked tirelessly to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. At the same...
Read More
Deep dive: The issues that drove the 2020 vote
By Tom Wilbur | November 13, 2020
The 2020 election provided much-needed clarity on the issues that matter most to Americans. Here are three key takeaways:
Read More
Understanding the emergency use authorization process for COVID-19 vaccines
By Richard Moscicki, M.D. | November 12, 2020
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop safe and effective vaccines to prevent infection, as well...
Read More
ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasion
By Guest Contributor | November 2, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
By Douglas Petersen | November 2, 2020
As the United States biopharmaceutical industry works around the clock to develop vaccines and treatments for COVID-19, it’s more important than ever that international trade policies facilitate...
Read More
Voters want to address the real drivers of health care costs for patients and the system
By Tom Wilbur | November 2, 2020
COVID-19 has understandably reshaped the health care conversation surrounding the upcoming election, with roughly one-fifth of voters citing the coronavirus pandemic as the priority issue heading...
Read More
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
By Nicole Longo | October 13, 2020
In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today,...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | October 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
By Stephen J. Ubl | October 1, 2020
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
Read More
Leading researchers to spotlight the critical role of biopharmaceutical R&D
By Andrew Powaleny | October 1, 2020
Biopharmaceutical researchers are at the heart of a robust American research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world.
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
